Evidence map›Paper›PMID 40364727›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

A pH-Sensitive Nanosized Covalent-Organic Polymer for Enhanced Tumor Photodynamic Immunotherapy by Hypoxia Relief and STAT3 Inhibition.

Lei Lei, Wenbin Dai, Jinchao Zhao, Angfeng Jiang, Haisheng Peng, Qiao Jin, Xiaojing Li, Zhe Tang

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Tumor Microenvironment-Responsive Nanomedicines for Potentiating Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lei LeiDepartment of General Surgery, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, 322000, China.
Wenbin DaiMOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310058, China.
Jinchao ZhaoDepartment of General Surgery, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, 322000, China.
Angfeng JiangDepartment of General Surgery, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, 322000, China.
Haisheng PengDepartment of Pharmacology, Medical College of Shaoxing University, Shaoxing, 312099, China.
Qiao JinMOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310058, China.ORCID https://orcid.org/0000-0002-6584-4111
Xiaojing LiDepartment of Gynecology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310058, China.
Zhe TangDepartment of Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310058, China.

Funding

joint fund of Shaoxing University and Shaoxing Institute of Zhejiang University 2023LHLG007National Natural Science Foundation of China 52473152Zhejiang Province Leading Geese Plan 2025C02132
6 · The paper itself

Abstract

Photodynamic therapy (PDT) is a promising cancer therapy modality by generating reactive oxygen species (ROS) and triggering immunogenic cell death. However, the therapeutic effect of PDT is strongly limited by tumor hypoxia and immunosuppressive landscape. Herein, a pH-sensitive nanosized covalent-organic polymer (COP), composed of the photosensitizer porphyrin and pyruvate kinase inhibitor vitamin K3 (VK3), is designed to overcome these issues. The signal transducer and activator of transcription 3 (STAT3) inhibitor WP1066 is further encapsulated into COPs to form a WP1066-loaded COP (TVW). As an inhibitor of pyruvate kinase, VK3 can reduce intracellular oxygen consumption by inhibiting the glycolytic pathway, leading to the alleviation of the tumor hypoxic microenvironment. The relief of tumor hypoxia by VK3 enhances photodynamic cytotoxicity by generating more ROS. Meanwhile, STAT3 acts as a major regulator of PD-L1, a key inhibitor that promotes immune escape. WP1066 effectively inhibits the expression of STAT3 and reduces PD-L1 expression, thereby significantly inhibiting tumor immune escape and enhancing antitumor efficacy in a synergistic manner. The antitumor capacity of photodynamic immunotherapy is extensively investigated in a murine subcutaneous hepatocellular carcinoma model. This photo-immunotherapy may provide an effective combination regimen for the efficient treatment of solid tumors such as hepatocellular carcinoma.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver Neoplasms, ExperimentalNanoparticle Drug Delivery SystemSTAT3 Transcription FactorAnimalsB7-H1 AntigenCell Line, TumorGene Expression Regulation, NeoplasticHydrogen-Ion ConcentrationImmunotherapyMaleMetal-Organic FrameworksMiceMice, Inbred C57BLPhotochemotherapyAntineoplastic AgentsB7-H1 AntigenMetal-Organic FrameworksNanoparticle Drug Delivery SystemPhotosensitizing AgentsPorphyrinsPyridinesPyruvate KinaseSTAT3 Transcription FactorTyrphostinsVitamin K 3WP1066covalent–organic polymerhypoxia reliefimmunotherapynanomedicinephotodynamic therapy

Identifiers

PMID40364727
PMCPMC12362755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.